RECOMMENDATIONS OF CROATIAN SOCIETIES ON TREATMENT OF MACROVASCULAR AND MICROVASCULAR COMPLICATIONS IN PATIENTS WITH METABOLIC SYNDROME AND DIABETES TYPE 2 – TREATMENT OF RESIDUAL RISK

Autori:

Željko Reiner, Veljko Božikov, Nikica Car, Aleksandar Knežević, Slaven Kokić, Željko Metelko, Davor Miličić, Stojan Polić, Luka Zaputović, Vanja Zjačić-Rotkvić

Sažetak

Sažetak. Rezultati više istraživanja pokazali su da usprkos postizanju ciljeva za ukupni i LDL-kolesterol, arterijski tlak i glikemiju sukladno smjernicama, mnogi bolesnici i dalje imaju velik preostali rizik od nastanka kardiovaskularnih bolesti, kako onih makrovaskularnih tako i mikrovaskularnih. To se osobito odnosi na bolesnike koji imaju dokazanu kardiovaskularnu bolest, šećernu bolest tipa 2, pretilost i/ili metabolički sindrom. Naime, oni često imaju aterogenu dislipidemiju koja je obilježena smanjenim koncentracijama HDL-kolesterola i povećanim trigliceridima u krvi. Kako bi se skrenula pozornost na taj problem, skupina stručnjaka napisala je ove preporuke o terapijskim mogućnostima smanjenja preostalog rizika. Preporuke su prihvatila hrvatska stručna i znanstvena društva (Hrvatsko društvo za aterosklerozu, Hrvatsko društvo za arterijsku hipertenziju, Hrvatsko kardiološko društvo, Hrvatsko dijabetološko društvo, Hrvatsko endokrinološko društvo, Hrvat¬sko društvo za debljinu, Hrvatsko internističko društvo i Hrvatsko društvo za kliničku farmakologiju).

Summary

Summary. Quite a number of studies have shown that despite achieving targets for total and LDL cholesterol, blood pressure and glycemia according to the guidelines, many patients remain at high residual risk for cardiovascular diseases (CVD), both macrovascular and microvascular. This is particularly true for patients with established CVD, type 2 diabetes, obesity and/or metabolic syndrome who have very often atherogenic dyslipidemia characterized by decreased plasma concentrations of HDL cholesterol and increased triglycerides. To address this issue a working group of experts has been established to produce this document in order to recommend therapeutic interventions for reducing this residual risk. This document has been endorsed by relevant Croatian scientific and professional societies (Croatian atherosclerosis socitey, Croatian hypertension society, Croatian cardiac society, Croatian diabetes society, Croatian endocrinology society, Croatian obesity society, Croatian internal medicine society and Croatian society for clinical pharmacology).